MDMégane Delourme

Mégane Delourme

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mégane Delourme has a total of 84 co-authors. Here are the top co-authors by number of shared publications:

  • Frédérique Magdinier

    Marseille Medical Genetics, MMG Aix‐Marseille University INSERM Marseille France

    2 shared publications
  • Ali Badache

    Centre de Recherche en Cancérologie de Marseille, Institut National de la Santé et de la Recherche Médicale, Institut Paoli-Calmettes, Aix-Marseille Université, Centre National de la Recherche Scientifique, Marseille, France

    1 shared publication
  • Ana Moreno-Izquierdo

    Servicio de Genética, Hospital 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain

    1 shared publication
  • Anthony Behin

    APHP, Service de Neuromyologie, Institut de Myologie, GH Pitié-Salpêtrière, Paris, France

    1 shared publication
  • Antoine Pegat

    Electroneuromyography and Neuromuscular Diseases Unit, Pierre Wertheimer Hospital, Hospices Civils de Lyon, Bron, France

    1 shared publication
  • Armelle Magot

    Centre de Référence des Maladies Neuromusculaires AOC, CHU de Nantes, Filnemus, Euro-NMD, Nantes, France

    1 shared publication

Latest Publications

  • La dystrophie facio-scapulo-humérale : du diagnostic aux aspects fonctionnels

    by MégAne Delourme

    La dystrophie facio-scapulo-humérale (FSHD) est caractérisée par une faiblesse asymétrique et progressive de certains groupes de muscles, initialement ceux de la face, de la ceinture scapulaire et des bras. Les symptômes apparaissent généralement à la fin de la 2ème décade de la vie. Il existe une grande variabilité clinique et une pénétrance incomplète. Génétiquement, deux types de FSHD ont été décrits. Dans 95% des cas, la FSHD1 est associée à la contraction du macrosatellite D4Z4. Dans les 5% restants (FSHD2), il n’y a pas de diminution du nombre de répétitions D4Z4. Des mutations du gène SMCHD1 sont retrouvées pour 90% de ces patients. Dans les deux types de FSHD, une hypométhylation du locus est retrouvée.L’objectif de ma thèse fut de contribuer à l’amélioration du diagnostic de la FSHD et de mieux comprendre les mécanismes physiopathologiques sous-jacents. Ainsi, mon projet s’est articulé autour de deux axes. Le premier axe, translationnel, était basé sur l’exploration d’une cohorte importante de patients afin d’approfondir l’étude des mécanismes moléculaires dans la FSHD. Nous nous sommes notamment intéressés aux remaniements complexes et à la méthylation dans les différents types de FSHD. Le deuxième axe, plus fondamental, s’est intéressé aux aspects fonctionnels de la FSHD, en utilisant un protocole de différenciation des cellules souches à pluripotence induite de patients en fibres musculaires innervées afin d’en étudier le transcriptome et l’architecture chromatinienne associée aux variants SMCHD1. Ainsi, mes travaux ont permis une meilleure compréhension de cette pathologie complexe qu’est la FSHD, d’autant d’un point de vue moléculaire que fonctionnel.

  • Open Access

    Personalized multichannel transcranial direct current electrical stimulation ( tDCS ) in drug‐resistant epilepsy: A SEEG based open‐labeled study

    by Fabrice Bartolomei, Maëva Daoud, Megane Delourme, Sophie Tardoski, Julia Makhalova, Eya Bourguiba, Samuel Medina Villalon, Stanislas Lagarde, Fabrice Wendling, Giulio Ruffini, et al.

    Objective: To evaluate the effects of personalized multichannel tDCS on seizure frequency, severity, quality of life, and psychiatric comorbidities in patients with drug‐resistant focal epilepsy. Secondary goals include assessing the safety and feasibility of this approach. Methods: This open‐label pilot study involved 16 patients with drug‐resistant focal epilepsy. Patients underwent 3 cycles of personalized multichannel tDCS over 6 months, targeting the EZ defined by stereoelectroencephalography (SEEG). Each cycle consisted of five consecutive days of tDCS, with two daily sessions of 20 min each. The primary endpoint was a reduction in seizure frequency, with secondary endpoints addressing quality of life (QOLIE‐31 scores), seizure severity (NHS3 scores), and psychiatric comorbidities (NDDI‐E and GAD‐7 scales). Results: Across all participants, a statistically significant 20% reduction in seizure frequency was observed ( p = 0.044). Six patients (37%) were identified as responders (≥50% seizure reduction), with one achieving seizure freedom. The mean seizure reduction among responders was 68%. Significant improvements were noted in overall quality of life (QOLIE‐31, p = 0.009), with greater benefits for patients with poorer baseline scores. No overall significant changes were observed in depression, anxiety, and seizure severity scores, though individual variability was noted. The treatment was well tolerated, with mild adverse events, primarily skin‐related. Significance: Personalized multichannel tDCS shows promise as a noninvasive therapeutic option for drug‐resistant focal epilepsy, with benefits in seizure reduction and quality of life. Although results were variable, the method's safety and feasibility support further exploration through randomized controlled trials to refine protocols, better select potential responders' patients, and validate findings. Plain Language Summary: This study tested a personalized brain stimulation technique called tDCS in people with difficult‐to‐treat epilepsy. The treatment led to fewer seizures in some patients and improved their quality of life. The approach was safe and caused only mild side effects. These results suggest that this type of noninvasive brain stimulation may be a helpful new option for people who do not benefit from medication or surgery.


  • SMCHD1 genetic variants in type 2 facioscapulohumeral dystrophy and challenges in predicting pathogenicity and disease penetrance

    by Laurène Gérard, Mégane Delourme, Charlotte Tardy, Benjamin Ganne, Pierre Perrin, Charlene Chaix, Jean Philippe Trani, Nathalie Eudes, Camille Laberthonnière, Karine Bertaux, et al.

    The molecular diagnosis of type 1 facioscapulohumeral muscular dystrophy (FSHD1) relies on the detection of a shortened D4Z4 array at the 4q35 locus. Until recently, the diagnosis of FSHD2 relied solely on the absence of a shortened D4Z4 allele in clinically affected patients. It is now established that most FSHD2 cases carry a heterozygous variant in the SMCHD1 gene. A decrease in D4Z4 DNA methylation is observed in both FSHD1 and FSHD2 patients. To refine the molecular diagnosis of FSHD2, we performed a molecular diagnosis of SMCHD1 in 54 patients with a clinical diagnosis of FSHD. All patients carry a D4Z4 array of more than 10 D4Z4 units, or a cis-duplication of the locus. Forty-eight of them carry a variant in SMCHD1 and six other cases are hemizygous for the 18p32 locus encompassing SMCHD1. Genetic and epigenetic analyses were considered to assess the pathogenicity of new SMCHD1 variants and of variants previously classified as likely pathogenic. In comparison to the healthy population and FSHD1 patients, we defined a threshold of 40% of methylation at the D4Z4 DR1 site as associated with SMCHD1 variants or SMCHD1 hemizygosity. We also showed that the number of D4Z4 on the shortest 4q allele ranges from 11 up to 35 units in these same patients. Using variant interpretation and protein structure prediction tools, we also highlight the difficulty in interpreting the impact of pathogenic variants on SMCHD1 function. Our study further emphasizes the intriguing relationship between D4Z4 methylation, SMCHD1 variants with SMCHD1 protein structure-function in FSHD.


  • Open Access

    Generation of the First Human In Vitro Model for McArdle Disease Based on iPSC Technology

    by María del Carmen Ortuño-Costela, Victoria Cerrada, Ana Moreno-Izquierdo, Inés García-Consuegra, Camille Laberthonnière, Mégane Delourme, Rafael Garesse, Joaquín Arenas, Carla Fuster García, Gema García García, et al.

    McArdle disease is a rare autosomal recessive disorder caused by mutations in the PYGM gene. This gene encodes for the skeletal muscle isoform of glycogen phosphorylase (myophosphorylase), the first enzyme in glycogenolysis. Patients with this disorder are unable to obtain energy from their glycogen stored in skeletal muscle, prompting an exercise intolerance. Currently, there is no treatment for this disease, and the lack of suitable in vitro human models has prevented the search for therapies against it. In this article, we have established the first human iPSC-based model for McArdle disease. For the generation of this model, induced pluripotent stem cells (iPSCs) from a patient with McArdle disease (harbouring the homozygous mutation c.148C>T; p.R50* in the PYGM gene) were differentiated into myogenic cells able to contract spontaneously in the presence of motor neurons and generate calcium transients, a proof of their maturity and functionality. Additionally, an isogenic skeletal muscle model of McArdle disease was created. As a proof-of-concept, we have tested in this model the rescue of PYGM expression by two different read-through compounds (PTC124 and RTC13). The developed model will be very useful as a platform for testing drugs or compounds with potential pharmacological activity.


  • Open Access

    HRAS germline mutations impair LKB1/AMPK signaling and mitochondrial homeostasis in Costello syndrome models

    by Laetitia Dard, Christophe Hubert, Pauline Esteves, Wendy Blanchard, Ghina Bou About, Lyla Baldasseroni, Elodie Dumon, Chloe Angelini, Mégane Delourme, Véronique Guyonnet-Dupérat, et al.

    Germline mutations that activate genes in the canonical RAS/MAPK signaling pathway are responsible for rare human developmental disorders known as RASopathies. Here, we analyzed the molecular determinants of Costello syndrome (CS) using a mouse model expressing HRAS p.G12S, patient skin fibroblasts, hiPSC-derived human cardiomyocytes, a HRAS p.G12V zebrafish model, and human fibroblasts expressing lentiviral constructs carrying HRAS p.G12S or HRAS p.G12A mutations. The findings revealed alteration of mitochondrial proteostasis and defective oxidative phosphorylation in the heart and skeletal muscle of CS mice that were also found in the cell models of the disease. The underpinning mechanisms involved the inhibition of the AMPK signaling pathway by mutant forms of HRAS, leading to alteration of mitochondrial proteostasis and bioenergetics. Pharmacological activation of mitochondrial bioenergetics and quality control restored organelle function in HRAS p.G12A and p.G12S cell models, reduced left ventricle hypertrophy in CS mice, and diminished the occurrence of developmental defects in the CS zebrafish model. Collectively, these findings highlight the importance of mitochondrial proteostasis and bioenergetics in the pathophysiology of RASopathies and suggest that patients with CS may benefit from treatment with mitochondrial modulators.